See more : Sagami Rubber Industries Co., Ltd. (5194.T) Income Statement Analysis – Financial Results
Complete financial analysis of Global Cord Blood Corporation (CO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Global Cord Blood Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Shandong Sacred Sun Power Sources Co.,Ltd (002580.SZ) Income Statement Analysis – Financial Results
- Baida Group Co.,Ltd (600865.SS) Income Statement Analysis – Financial Results
- Oklo Inc. (OKLO) Income Statement Analysis – Financial Results
- Oncopeptides AB (publ) (ONCO.ST) Income Statement Analysis – Financial Results
- Torrent Gold Inc. (TGLD.CN) Income Statement Analysis – Financial Results
Global Cord Blood Corporation (CO)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.globalcordbloodcorp.com
About Global Cord Blood Corporation
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24B | 1.16B | 1.22B | 986.75M | 936.77M | 759.98M | 663.00M | 635.12M | 572.86M | 526.12M | 380.49M | 339.53M | 261.54M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 183.31M | 178.95M | 189.13M | 186.03M | 181.48M | 142.64M | 144.60M | 130.61M | 106.23M | 106.62M | 86.66M | 77.38M | 65.73M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.06B | 980.69M | 1.03B | 800.73M | 755.29M | 617.34M | 518.40M | 504.51M | 466.63M | 419.50M | 293.83M | 262.16M | 195.81M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 85.26% | 84.57% | 84.52% | 81.15% | 80.63% | 81.23% | 78.19% | 79.44% | 81.46% | 79.73% | 77.22% | 77.21% | 74.87% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.30M | 23.77M | 21.11M | 14.69M | 12.72M | 10.37M | 8.96M | 9.91M | 9.77M | 8.46M | 7.62M | 6.96M | 5.82M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 187.06M | 174.36M | 190.23M | 169.32M | 243.50M | 189.94M | 169.95M | 131.68M | 112.24M | 108.05M | 89.70M | 83.79M | 53.32M | 11.20M | 0.00 | 0.00 |
| Selling & Marketing | 241.73M | 237.69M | 261.96M | 235.06M | 219.20M | 178.48M | 148.16M | 127.93M | 112.69M | 93.68M | 61.68M | 47.58M | 39.48M | 0.00 | 0.00 | 0.00 |
| SG&A | 428.79M | 412.05M | 452.19M | 404.38M | 462.70M | 368.42M | 318.11M | 259.61M | 224.93M | 201.73M | 151.37M | 131.38M | 92.80M | 11.20M | 4.01M | 66.28K |
| Other Expenses | 6.27M | 8.16M | 7.39M | 5.70M | 4.23M | 5.97M | -113.00K | 861.00K | 2.21M | 203.00K | 0.00 | 0.00 | 0.00 | 594.98K | 220.52K | 166.41K |
| Operating Expenses | 451.08M | 435.82M | 473.30M | 419.07M | 475.42M | 352.47M | 327.07M | 269.52M | 234.71M | 210.19M | 158.99M | 138.34M | 98.61M | 11.80M | 4.23M | 232.69K |
| Cost & Expenses | 634.39M | 614.77M | 662.43M | 605.10M | 656.91M | 495.11M | 471.67M | 400.13M | 340.93M | 316.81M | 245.65M | 215.71M | 164.34M | 11.80M | 4.23M | 232.69K |
| Interest Income | 32.61M | 30.90M | 25.36M | 25.32M | 21.94M | 17.42M | 18.22M | 18.25M | 16.87M | 15.06M | 13.43M | 9.07M | 6.41M | 4.11M | 0.00 | 250.79K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 3.26M | 119.42M | 107.97M | 101.10M | 70.08M | 70.10M | 3.29M | 2.61M | 2.43M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.91M | -26.82M | 12.97M | 52.37M | 50.59M | 50.48M | 50.17M | 50.61M | 37.07M | 35.87M | 29.36M | 23.48M | 20.43M | 3.92M | 7.10M | 250.79K |
| EBITDA | 628.78M | 518.05M | 572.00M | 404.75M | 353.60M | 333.71M | 299.10M | 306.33M | 297.44M | 256.96M | 174.26M | 151.71M | 96.81M | -7.88M | 2.87M | 18.11K |
| EBITDA Ratio | 50.58% | 44.67% | 46.83% | 41.02% | 37.75% | 43.91% | 45.11% | 48.23% | 51.92% | 48.84% | 45.80% | 44.68% | 37.02% | 0.00% | 0.00% | 0.00% |
| Operating Income | 608.87M | 544.87M | 559.03M | 381.66M | 279.86M | 264.87M | 191.33M | 235.00M | 231.93M | 209.31M | 134.84M | 123.82M | 97.19M | -11.80M | -4.23M | -232.69K |
| Operating Income Ratio | 48.97% | 46.99% | 45.77% | 38.68% | 29.88% | 34.85% | 28.86% | 37.00% | 40.49% | 39.78% | 35.44% | 36.47% | 37.16% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 18.97M | 65.88M | 19.78M | -25.20M | 23.67M | -98.55M | -50.00M | -79.88M | -41.00M | -51.13M | 16.76M | 8.32M | -17.53M | 3.92M | 7.10M | 250.79K |
| Income Before Tax | 627.84M | 610.75M | 578.81M | 356.46M | 303.54M | 166.31M | 141.33M | 155.12M | 190.92M | 158.19M | 151.60M | 132.14M | 79.66M | -7.88M | 2.87M | 18.11K |
| Income Before Tax Ratio | 50.50% | 52.67% | 47.39% | 36.12% | 32.40% | 21.88% | 21.32% | 24.42% | 33.33% | 30.07% | 39.84% | 38.92% | 30.46% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 118.35M | 94.55M | 101.08M | 61.26M | 62.66M | 37.62M | 50.00M | 47.33M | 58.40M | 38.54M | 9.63M | 33.93M | 24.77M | -4.11M | -7.47M | -18.11K |
| Net Income | 501.07M | 508.25M | 470.72M | 291.12M | 237.10M | 126.19M | 90.97M | 107.29M | 131.90M | 112.45M | 131.98M | 91.70M | 49.18M | -7.88M | 2.87M | 18.11K |
| Net Income Ratio | 40.30% | 43.83% | 38.54% | 29.50% | 25.31% | 16.60% | 13.72% | 16.89% | 23.03% | 21.37% | 34.69% | 27.01% | 18.80% | 0.00% | 0.00% | 0.00% |
| EPS | 4.12 | 4.18 | 3.87 | 2.40 | 1.99 | 1.59 | 1.25 | 1.36 | 1.60 | 1.49 | 1.79 | 1.31 | 0.69 | -1.13 | 0.41 | 0.01 |
| EPS Diluted | 4.12 | 4.18 | 3.87 | 2.40 | 1.99 | 1.59 | 1.25 | 1.36 | 1.60 | 1.49 | 1.79 | 1.31 | 0.66 | -1.13 | 0.41 | 0.01 |
| Weighted Avg Shares Out | 121.55M | 121.55M | 121.55M | 121.30M | 119.14M | 79.36M | 72.78M | 78.89M | 82.44M | 75.47M | 73.73M | 70.00M | 71.27M | 7.00M | 7.00M | 1.49M |
| Weighted Avg Shares Out (Dil) | 121.55M | 121.55M | 121.55M | 121.30M | 119.14M | 79.36M | 72.78M | 78.89M | 82.44M | 75.47M | 73.73M | 70.00M | 74.51M | 7.00M | 7.00M | 1.49M |
Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 7, 2021
HONG KONG , Sept. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the...
Global Cord Blood Corporation (CO) Q1 2022 Results - Earnings Call Transcript
Global Cord Blood Corporation (CO) Q1 2022 Results - Earnings Call Transcript
Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2022
1Q22 Added 19,673 New Subscribers Revenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million) Gross Profit Up 12.6% YoY to RMB267.3 Million ($41.4 Million) Operating Income Up 17.3% YoY to RMB156.6 Million ($24.2 Million) Non-GAAP Operating Income Up 15.5% YoY to...
Global Cord Blood Is An Undervalued Business With Accelerating Growth, Benefiting From China's Policy Changes
Global Cord Blood Is An Undervalued Business With Accelerating Growth, Benefiting From China's Policy Changes
Global Cord Blood Corporation Files Annual Report on Form 20-F
HONG KONG, July 29, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed...
Global Cord Blood: New China Policy Catalyst, 146% Net Cash And 24% EPS CAGR
Global Cord Blood had a decent quarter, with subscriber growth improving both YoY and QoQ.
Global Cord Blood Corporation (CO) Management on Q4 2021 Results - Earnings Call Transcript
Global Cord Blood Corporation (CO) Management on Q4 2021 Results - Earnings Call Transcript
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2021
Added 19,367 New Subscribers in 4Q21 Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million) Net Income Attributable Up 31.7% YoY to RMB127.7 million ($19.5 million) Operating Cash Flow Up 134.6% YoY to RMB211.1 million ($32.2 million) Conference Call to...
Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results
HONG KONG, June 22, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited...
Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal
HONG KONG, March 15, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response...
Source: https://incomestatements.info
Category: Stock Reports